Published study on Parkinson's drug contradicts previous concerns

02/18/2005 | Los Angeles Times (tiered subscription model)

A study published in the Journal of Neurology, days after Amgen stopped giving its trial GDNF drug to Parkinson's patients in company-supported studies, says the medication led to improved mobility in seven of the 10 patients who received the medicine. The new study's author urged Amgen to reconsider its decision, but an Amgen spokeswoman said she was unaware of the study from the University of Kentucky team.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC